Related Experiment Video
Updated: Aug 15, 2026
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
Published on: July 16, 2012
HIV and hepatitis C coinfection
Insights
Coinfection with HIV and viral hepatitis (HCV or HBV) poses health risks, potentially worsening liver damage and complicating treatment. However, with careful management, coinfected individuals can achieve successful treatment outcomes for both conditions.
Area of Science:
- Infectious Diseases
- Hepatology
- Virology
Background:
- Coinfection with Human Immunodeficiency Virus (HIV) and viral hepatitis (Hepatitis C Virus [HCV] or Hepatitis B Virus [HBV]) is a significant public health issue due to shared transmission routes.
- HCV and HBV infections can lead to severe liver conditions like cirrhosis and cancer, with HIV often exacerbating hepatitis progression and liver damage.
Discussion:
- HIV coinfection may negatively impact immune system recovery during antiretroviral therapy and increase the risk of drug-induced liver toxicity.
- Managing coinfection presents challenges due to potential drug interactions and exacerbated side effects between HIV and hepatitis treatments.
- Current expert recommendations prioritize controlling HIV before initiating HCV treatment.
Key Insights:
- HIV infection can accelerate the progression of hepatitis C and B, increasing the risk of liver damage.
- While HCV generally doesn't accelerate HIV disease, coinfection can hinder immune recovery post-antiretroviral therapy.
- Successful treatment is achievable for most coinfected patients with meticulous management strategies.
Outlook:
- Emerging research indicates that individuals with well-controlled HIV and adequate CD4 counts may experience outcomes similar to those with HCV alone.
- Further research is needed to fully elucidate the long-term effects of HBV/HIV coinfection on HIV disease progression.
- Optimizing treatment protocols for coinfected patients remains a critical area for improving patient prognosis and public health outcomes.
Abstract:
Coinfection with HIV and the hepatitis C virus (HCV) or hepatitis B virus (HBV) is a growing public health concern. Because the diseases are spread in similar ways--notably through shared use of needles to inject drugs and sexual activity--many people are coinfected with HIV and HCV, HIV and HBV, or even all three viruses. Hepatitis C and hepatitis B are viral infections of the liver; over time they can lead to serious consequences including liver cirrhosis and liver cancer. Most studies show that HIV infection leads to more aggressive hepatitis C or hepatitis B and a higher risk of liver damage. Studies of how HCV and HBV affect HIV disease are less clear. Most research shows that HCV does not accelerate HIV disease progression, but HIV/HCV coinfection may impair immune system recovery after starting antiretroviral therapy. Coinfection can complicate treatment. People with liver damage due to chronic hepatitis are more likely to experience hepatotoxicity (liver toxicity) related to anti-HIV drugs. In addition, drugs used to treat HIV and hepatitis can interact and side effects may be exacerbated. Most experts recommend that HIV should be controlled first before a person begins HCV treatment. With careful management, most people with HIV/HCV or HIV/HBV coinfection can be successfully treated for both diseases. In fact, several recent studies suggest that HIV/HCV-coinfected people with well-controlled HIV disease and relatively high CD4 cell counts may do as well as those with HCV alone.
Related Concept Videos
01:10Retrovirus Life Cycles
01:26Sexually Transmitted Infections
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:27Cytomegalovirus Disease
01:25Hepatitis
01:28Viral Hepatitis I: Introduction